RELIEF study¹

• The RELIEF study was conducted as a longitudinal retrospective cohort study.
• Data source was the French nationwide reimbursement claim database SNDS.
• Data on hospitalisation related to acute diabetic complications were recorded in the year prior to first FreeStyle Libre sensor claim (index date for initiation), and in the year after (FSL users Aug 1, 2017–Dec 31, 2017).
• Blood test strip usage was determined based on reimbursement for 12 months prior to FreeStyle Libre system initiation.

• 33,165 people with T1D and 40,846 people with T2D, initiating the FreeStyle Libre system during the study period (2017/08/01 to 2017/12/31) were identified. Patients of all ages were included and were not stratified by age.
• Patients on multiple daily injections (MDI; n=46,828) and continuous subcutaneous insulin infusion (CSII; n=18,593) accounted for 88 % of the study population. Patients with T2D treated with a single basal insulin injection or with oral agents only accounted for 12 % of the study population.

Data on hospitalisation related to acute diabetic complications before and after availability of the FreeStyle Libre system were collected based on their ICD-10 codes:


• T1D with ketoacidosis
• T2D with ketoacidosis
• Drug-induced hypoglycaemia without coma
• Other hypoglycaemia
• Hypoglycaemia, unspecified
• Poisoning by adverse effects of insulin and oral hypoglycaemic
• T1D with coma
• T2D with coma
• Diabetes unspecified with coma
• Hyperglycaemia-related stays

• Reduced incidence of hospitalisation for DKA and diabetes-related comas and dysglycaemia in patients using the FreeStyle Libre system¹
• Overall hospitalisation rates for DKA was reduced by 56.2 % in T1D (Figure 1a) and 52.1 % in T2D (Figure 1b).
• Diabetes-related comas were reduced by 39.6 % in T1D and by 31.9 % in T2D following the initiation of the FreeStyle Libre system (Figure 1 a,b).
• Hospitalisations rates for hypoglycaemia and hyperglycaemia in people with T2D decreased by 10.8 % and 26.5 %, respectively (Figure 1b).





  

• The reduction in hospitalisation rate in the total study population was most marked for people who were noncompliant with SMBG and for those with highest acquisition of SMBG before FreeStyle Libre initiation (Figure 2).
• This result was consistent in the T1D and T2D subpopulations.
• The reduction in rates of hospitalisation with acute diabetes complications in the total study population was
54.0 % for patients using 0 SMBG tests/day and 51.2 % for patients using >5 tests/day, respectively (Figure 2).